Sign up to save your podcasts
Or
Share Episode 22: Celebrating 25 years of TKIs in CML
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 22: Celebrating 25 years of TKIs in CML
Marking a major milestone in chronic myeloid leukemia treatment
Tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia, a condition that had limited therapeutic options before.
In this 25th year since the first phase 2 trials of the first TKI, we speak to a researcher and clinician who has been involved since the early days. Dr. Jorge Cortes shares his experience and talks about the impact of these drugs, not only in the treatment of CML but also more widely.
View all episodes
By Editorial office Springer MedicineMarking a major milestone in chronic myeloid leukemia treatment
Tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia, a condition that had limited therapeutic options before.
In this 25th year since the first phase 2 trials of the first TKI, we speak to a researcher and clinician who has been involved since the early days. Dr. Jorge Cortes shares his experience and talks about the impact of these drugs, not only in the treatment of CML but also more widely.